ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Indivior PLC

Indivior PLC (INDV)

11.99
0.09
(0.76%)
Closed December 24 3:00PM
11.99
0.00
(0.00%)
After Hours: 3:20PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
11.99
Bid
11.21
Ask
12.41
Volume
1,086,411
11.85 Day's Range 12.00
7.33 52 Week Range 23.22
Market Cap
Previous Close
11.90
Open
12.00
Last Trade
1
@
12.27
Last Trade Time
Financial Volume
US$ 12,998,343
VWAP
11.9645
Average Volume (3m)
1,330,280
Shares Outstanding
129,575,205
Dividend Yield
-
PE Ratio
628.57
Earnings Per Share (EPS)
0.02
Revenue
1.09B
Net Profit
2M

About Indivior PLC

Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs based on buprenorphine for treatment of opioid dependence. The vast majority of Indivior's revenue is generated in the United States, followed by... Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs based on buprenorphine for treatment of opioid dependence. The vast majority of Indivior's revenue is generated in the United States, followed by the rest of the world. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Berkshire, Gbr
Founded
-
Indivior PLC is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker INDV. The last closing price for Indivior was US$11.90. Over the last year, Indivior shares have traded in a share price range of US$ 7.33 to US$ 23.22.

Indivior currently has 129,575,205 shares outstanding. The market capitalization of Indivior is US$1.54 billion. Indivior has a price to earnings ratio (PE ratio) of 628.57.

INDV Latest News

Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024

Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.1-0.82712985938812.0912.1511.2809150623011.69839733CS
41.1911.018518518510.812.199910.62131706611.53297447CS
122.3223.99172699079.6712.19997.33133028010.03715372CS
26-4.38-26.756261453916.3716.697.33105948710.54929526CS
52-3.19-21.014492753615.1823.227.3359221611.2956402CS
156-14.51-54.754716981126.526.57.3339043511.42716495CS
260-14.51-54.754716981126.526.57.3339043511.42716495CS

INDV - Frequently Asked Questions (FAQ)

What is the current Indivior share price?
The current share price of Indivior is US$ 11.99
How many Indivior shares are in issue?
Indivior has 129,575,205 shares in issue
What is the market cap of Indivior?
The market capitalisation of Indivior is USD 1.54B
What is the 1 year trading range for Indivior share price?
Indivior has traded in the range of US$ 7.33 to US$ 23.22 during the past year
What is the PE ratio of Indivior?
The price to earnings ratio of Indivior is 628.57
What is the cash to sales ratio of Indivior?
The cash to sales ratio of Indivior is 1.15
What is the reporting currency for Indivior?
Indivior reports financial results in USD
What is the latest annual turnover for Indivior?
The latest annual turnover of Indivior is USD 1.09B
What is the latest annual profit for Indivior?
The latest annual profit of Indivior is USD 2M
What is the registered address of Indivior?
The registered address for Indivior is 234 BATH ROAD, SLOUGH, BERKSHIRE, SL1 4EE
What is the Indivior website address?
The website address for Indivior is www.indivior.com
Which industry sector does Indivior operate in?
Indivior operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BAOSBaosheng Media Group Holdings Ltd
US$ 7.10
(310.40%)
58.74M
HOURHour Loop Inc
US$ 4.40
(207.69%)
97.42M
GTIGraphjet Technology
US$ 0.61
(168.72%)
265.48M
CREVCarbon Revolution Public Ltd
US$ 9.16
(135.48%)
26.95M
AVGRAvinger Inc
US$ 1.45
(125.72%)
107.53M
SLGLSol Gel Technologies Ltd
US$ 0.9798
(-40.62%)
3.07M
DRCTDirect Digital Holdings Inc
US$ 3.71
(-32.55%)
23.82M
CHEKCheck Cap Ltd
US$ 1.55
(-31.11%)
3.49M
SYTASiyata Mobile Inc
US$ 0.5178
(-30.83%)
2.63M
BTFValkyrie ETF Trust II CoinShares Bitcoin and Ether Stratagy ETF
US$ 15.47
(-30.38%)
147.98k
SVMHSRIVARU Holding Ltd
US$ 0.0338
(20.71%)
280.27M
GTIGraphjet Technology
US$ 0.61
(168.72%)
265.48M
LITMSnow Lake Resources Ltd
US$ 0.5849
(52.84%)
181.22M
LCIDLucid Group Inc
US$ 3.20
(3.23%)
108.75M
RGTIRigetti Computing Inc
US$ 11.35
(3.56%)
108.38M

INDV Discussion

View Posts
Monksdream Monksdream 9 months ago
INDV over $20
👍️0
Renee Renee 2 years ago
IZQVF: effective Oct. 10,2022 a one for 5 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
👍️0
cash4 cash4 5 years ago
March 23, 2020
Statement on the Coronavirus and Global Supply of Medicines
Indivior is closely monitoring developments relating to COVID-19 (novel coronavirus) outbreak.
Our priority remains the ongoing supply of medicines to healthcare providers and patients, the
health and safety of our employees and the well-being of the patients we serve.
We are actively managing our global supply chains to minimize any potential disruption. Our
executive management and supply team are together working with internal and external business
partners and regulatory authorities to assess and mitigate the potential impact of COVID-19. We are
committed to helping ensure that patients will continue to have an ongoing supply of their
medication. Based on our assessment and environment we do not currently expect to have any
material supply interruptions.
We are also following guidelines provided by international health authorities and all global, national
and local government mandates regarding measures to keep our workforce and communities safe.
We have instituted a remote work policy for office and field-based staff leveraging all available
technology to ensure essential activities will continue to provide patients, healthcare providers and
other key stakeholders with the supports they need.
We will continue to monitor the situation closely, placing the needs of patients first at all times.
👍️0

Your Recent History

Delayed Upgrade Clock